Somerset Indus Capital Partners Announces Close of Fund at $ 288 Mn

The capital will be deployed in scalable healthcare business solutions delivering affordable, accessible quality care across healthcare delivery, pharmaceuticals, medical devices, diagnostics, and allied sectors.

Mumbai-based healthcare-focused private equity firm, Somerset Indus Capital Partners, has successfully closed its third fund, Fund III, at $288 million, exceeding its initial target of USD 250 million.

The funding round saw robust participation from diverse global institutional investors, including Development Finance Institutions (DFIs), global investment firms, domestic financial institutions, insurance companies, funds of funds, family offices, and impact investors across Europe, the United States, and Southeast Asia.

The fund aims to address its ongoing efforts to focus on healthcare access gaps across India’s “missing middle,” especially in Tier II and Tier III markets.

The Fund III will primarily focus on growth-stage investments, targeting companies that demonstrate scalable business models and strong market potential.

The capital will be deployed in scalable healthcare business solutions delivering affordable, accessible quality care across healthcare delivery, pharmaceuticals, medical devices, diagnostics, and allied sectors.

Commenting on the new funding, Avinash Kenkare, Partner, Somerset Indus Capital Partners, said, “The successful fund raise is a strong endorsement of our strategy and execution capabilities. We are grateful for the continued trust of our Limited Partners who share our conviction that impact and financial performance can be mutually reinforcing.”

Reportedly, through Fund III, Somerset has already made three investments, including Cyrix Healthcare (MedTech servicing), Printmann Offset (pharmaceutical packaging), and NU Hospitals (a nephrology and urology-focused single specialty hospital chain).

The private equity firm typically invests between $15 million and $40 million in each portfolio company. Through co-investment syndication with its limited partner (LP) network, the firm also has the flexibility to participate in larger deals, with total investment sizes ranging between $60 million and $80 million.

The additional capital is expected to support larger and more transformative opportunities across segments such as preventive care, OPD-linked insurance, healthcare financing, embedded insurance solutions, value-focused generics, India-centric MedTech innovation, and diagnostics platforms aimed at improving accessibility and standardisation beyond metro markets.

Stay tuned for more such updates on Digital Health News